In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection.
Anti-Bacterial Agents
/ pharmacology
Auranofin
/ pharmacology
Clostridioides difficile
/ drug effects
Clostridium Infections
/ drug therapy
Drug Repositioning
Metronidazole
/ pharmacology
Microbial Sensitivity Tests
Microbial Viability
/ drug effects
Spores, Bacterial
/ drug effects
Vancomycin
/ pharmacology
Journal
Drugs in R&D
ISSN: 1179-6901
Titre abrégé: Drugs R D
Pays: New Zealand
ID NLM: 100883647
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
pubmed:
8
5
2020
medline:
4
2
2021
entrez:
8
5
2020
Statut:
ppublish
Résumé
Clostridium difficile infection is the leading cause of hospital-acquired gastrointestinal infection and incidence rates continue to rise. Clostridium difficile infection is becoming increasingly complex to treat owing to the rise in treatment failures and recurrent infections. There is a clear need for new therapeutic options for the management of this disease. This study aimed to assess auranofin, a drug approved for the treatment of arthritis, as a treatment for C. difficile infection. Previous investigations have demonstrated potential antimicrobial activity of auranofin against C. difficile and other organisms. The activity of auranofin was assessed by in vitro investigations of its effect on C. difficile M7404 growth, vegetative cell viability, and spore viability. Activity of auranofin was also compared to that of the current treatments, metronidazole and vancomycin. Auranofin showed bactericidal activity at concentrations as low as 4.07 µg/mL, effectively reducing bacterial cell density by 50-70% and the viable vegetative cell and spore yields by 100%. The activity of auranofin was shown to be non-inferior to that of metronidazole and vancomycin. Auranofin is highly efficacious against C. difficile M7404 in vitro and has the potential to be an ideal therapeutic option for the treatment of C. difficile infection.
Sections du résumé
BACKGROUND
BACKGROUND
Clostridium difficile infection is the leading cause of hospital-acquired gastrointestinal infection and incidence rates continue to rise. Clostridium difficile infection is becoming increasingly complex to treat owing to the rise in treatment failures and recurrent infections. There is a clear need for new therapeutic options for the management of this disease.
OBJECTIVE
OBJECTIVE
This study aimed to assess auranofin, a drug approved for the treatment of arthritis, as a treatment for C. difficile infection. Previous investigations have demonstrated potential antimicrobial activity of auranofin against C. difficile and other organisms.
METHODS
METHODS
The activity of auranofin was assessed by in vitro investigations of its effect on C. difficile M7404 growth, vegetative cell viability, and spore viability. Activity of auranofin was also compared to that of the current treatments, metronidazole and vancomycin.
RESULTS
RESULTS
Auranofin showed bactericidal activity at concentrations as low as 4.07 µg/mL, effectively reducing bacterial cell density by 50-70% and the viable vegetative cell and spore yields by 100%. The activity of auranofin was shown to be non-inferior to that of metronidazole and vancomycin.
CONCLUSIONS
CONCLUSIONS
Auranofin is highly efficacious against C. difficile M7404 in vitro and has the potential to be an ideal therapeutic option for the treatment of C. difficile infection.
Identifiants
pubmed: 32377889
doi: 10.1007/s40268-020-00306-3
pii: 10.1007/s40268-020-00306-3
pmc: PMC7419417
doi:
Substances chimiques
Anti-Bacterial Agents
0
Metronidazole
140QMO216E
Auranofin
3H04W2810V
Vancomycin
6Q205EH1VU
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
209-216Subventions
Organisme : National Health and Medical Research Council
ID : GNT9000198
Références
J Infect Dis. 2013 May 15;207(10):1498-504
pubmed: 23420906
Mol Microbiol. 1998 Jan;27(1):107-20
pubmed: 9466260
J Bacteriol. 2009 Jun;191(12):4035-40
pubmed: 19363113
Inflammopharmacology. 2008 Jun;16(3):112-25
pubmed: 18523733
Infect Immun. 2012 Aug;80(8):2704-11
pubmed: 22615253
Metallomics. 2010 Feb;2(2):112-6
pubmed: 21069141
Essays Biochem. 2017 Mar 3;61(1):81-88
pubmed: 28258232
J Antimicrob Chemother. 2014 Feb;69(2):451-62
pubmed: 24003182
J Antimicrob Chemother. 2007 Apr;59(4):705-10
pubmed: 17337513
Nature. 2009 Apr 30;458(7242):1176-9
pubmed: 19252482
Nat Rev Microbiol. 2011 Apr;9(4):233-43
pubmed: 21358670
J Biol Inorg Chem. 2009 May;14(4):507-19
pubmed: 19165513
Drugs R D. 2015 Mar;15(1):13-20
pubmed: 25698589
Intern Med J. 2016 Apr;46(4):479-93
pubmed: 27062204
Int J Antimicrob Agents. 2019 Jan;53(1):54-62
pubmed: 30273668
J Bacteriol. 2006 Dec;188(24):8487-95
pubmed: 17041035